Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.63 |
| ▸ | CA1 | P00915 | 12/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.60 |
| ▸ | CA9 | Q16790 | 6/20 | 0.60 |
| ▸ | CA4 | P22748 | 6/20 | 0.60 |
| ▸ | CA6 | P23280 | 4/20 | 0.60 |
| ▸ | CA5A | P35218 | 4/20 | 0.60 |
| ▸ | CA7 | P43166 | 4/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9492256 | 0.98 | CA2 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL10731766 | 0.87 | CA2 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL10724982 | 0.87 | CA2 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL10917795 | 0.87 | CA2 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL18882540 | 0.84 | CA2 (0.62) | CA2CA1CA12CA9CA4 | |
| SCHEMBL17132575 | 0.82 | RORC (0.49) | CA2 | |
| SCHEMBL26765124 | 0.82 | CA2 (0.61) | CA2CA1CA12CA9CA4 | |
| SCHEMBL21657132 | 0.82 | CA2 (0.66) | CA2CA1CA12CA9CA4 | |
| SCHEMBL19176437 | 0.81 | CA2 (0.65) | CA2CA1CA12CA9CA4 | |
| SCHEMBL12614485 | 0.81 | CA2 (0.79) | CA2CA1CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-27 | — | — | US | disclosed |
| US-9657009-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
| US-9551721-B2 | Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-24 | — | — | US | disclosed |
| US-8835470-B2 | Mandelamide heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-16 | — | — | US | disclosed |
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-7598247-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | MEDIGENE LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
| US-7276505-B2 | Immunomodulating heterocyclic compounds | MEDIGENE LIMITED (GB) | 2007-10-02 | — | — | US | disclosed |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | AVIDEX LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-0671660-B1 | Lead-frame forming material | FUJI PHOTO FILM CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-5670293-A | LIGHT SENSITIVE MATERIAL WITH COPPER OR NICKEL ALLOYS, DRYING A PHOTOSENSITIVE LAYER AND WINDING THE COATED WEB INTO STRIPS AND STACKING | FUJI PHOTO FILM CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| EP-0671660-A2 | Lead-frame forming material | FUJI PHOTO FILM CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544133-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | CA2 4624/4885CA1 4882/4885CA12 4885/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | CA2 1563/4885CA1 2878/4885CA12 3803/4885 |
| US-10023562-B2 | Heteroaryl substituted pyridyl compounds useful as kinase modulators | IRAK4, IRAK3, IRAK2 | CA2 4624/4885CA1 4882/4885CA12 4885/4885 |
| US-20080045527-A1 | Immunomodulating Heterocyclic Compounds | CD40, CD40LG, NGFR | CA2 2508/4885CA1 2084/4885CA12 1857/4885 |
| US-20070021428-A1 | Immunomodulating heterocyclic compounds | CD40, CD40LG, NGFR | CA2 2376/4885CA1 1652/4885CA12 1512/4885 |
| US-20170210730-A1 | HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS | IRAK4, IRAK3, IRAK2 | CA2 4624/4885CA1 4882/4885CA12 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.